In CheckMate 009/RCC and CheckMate 038-P1/melanoma, serum samples were evaluated at two on-treatment timepoints, allowing investigation of the relationship between change in sPD-L1 and outcome. The gene discussed is SPDL1; the disease is renal cell carcinoma.